Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-072815
Filing Date
2025-05-15
Accepted
2025-05-15 16:59:28
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13291
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 101219
  Complete submission text file 0000950170-25-072815.txt   154996
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Subject) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-84090 | Film No.: 25955054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

EIN.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G